Xanthine derivatives, their preparation and their use in pharmaceutical compositions
View Patent ↗Compounds of formula (I) wherein R 1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted, and R 2 to R 4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis using these compounds.
1. The compound of formula (I)
wherein:
R 1 is a [2-(cyclopropylcarbonylamino)phenyl]carbonylmethyl or [2-(pyridylcarbonyl-amino)phenyl]carbonylmethyl group;
R 2 is a methyl group;
R 3 is a 2-buten-1-yl, 3-methyl-2-buten-1-yl, or a 2-butyn-1-yl group; and
R 4 is a (3-aminopiperidin-1-yl) group,
or a prodrug or salt thereof.
2. A compound selected from:
(1) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine;
(2) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine;
(3) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-aminopiperidin-1-yl)xanthine;
(4) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7(-2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine;
(5) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(-2-butyn-1-yl)-8-((S)-3-aminopiperidin-1-yl)xanthine;
(6) 1-[2-(2-{[(pyridin-2-yl)carbonyl]amino }phenyl)-2-oxoethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-aminopiperidin- 1-yl)xanthine,
or a prodrug or salt thereof.
3. The compound of formula (I) according to claim 1 , wherein the compound is a physiologically acceptable salt.
4. The compound according to claim 2 , wherein the compound is a physiologically acceptable salt.
5. A pharmaceutical composition comprising a compound of formula (I) according to claims 1 and an inert carrier or diluent.
6. The pharmaceutical composition according to claim 5 , wherein the compound of formula (I) is incorporated with the inert carrier or diluent by mixing.
7. A method of treating type II diabetes mellitus, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 1 or 2 .
8. A method of treating or preventing type II diabetes mellitus or obesity, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 1 or 2 .
9. A pharmaceutical composition comprising a compound according to claim 2 and an inert carrier or diluent.
10. The pharmaceutical composition according to claim 9 , wherein the compound is incorporated with the inert carrier or diluent by mixing.